張俊彥-合聘

JY Chang張俊彥  合聘特聘研究員
生技與藥物研究所
Email: jychang@nhri.edu.tw
台北醫學大學網頁

 

EDUCATION

  • 1982 M.D., National Defense Medical Center, Taipei, Taiwan, R.O.C.

PROFESSIONAL EXPERIENCES

2022/11- Dean,Research Center of Cancer Translation Medicine, Taipei Medical University, Taipei,Taiwan
2020/11-2022/10 Director,Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
2020/08- Distinguished Investigator and Attending Physician of National Institute of Cancer Research, NHRI
2020/08 Emeritus Professor, National Cheng Kung University
2019/02 Executive Vice President, National Cheng Kung University
2019/02-2020/08 Director of University Center for Bioscience and biotechnology, NCKU
2014/08-2019/07 Distinguished Professor and Dean, College of Medicine, National Cheng Kung University
2013/08-2014/07 Professor and Dean, College of Medicine, National Cheng Kung University
2010/08-2011/07 製藥與國家型生技-癌症組 召集人
2008/09-2018/05 Distinguished Investigator, National Institute of Cancer Research, NHRI, Taiwan
2008/01-2013/07 Director, National Institute of Cancer Research, NHRI, Taiwan
2007/08-now Attending Physician of Division of hematology/Oncology, NCKUH
2007/08-2013/07 Joined Professor, College of Medicine, National Cheng Kung University
2006/01-2007/12 Deputy Director, National Institute of Cancer Research, NHRI, Taiwan
2004/06-2008 Chairman, Safety and Data Monitoring committee, TCOG, Taiwan
2004/04-2008/08 Investigator, Division of Cancer Research, NHRI, Taiwan
2003/08-2007/07 Adjunct Professor, Internal Medicine, NDMC, Taiwan
2003-2005 常務理事, Chinese Oncology Society, Taiwan
2001 Board member, Chinese Oncology Society, Taiwan
2000/09-2004/03 Associate investigator, Division of Cancer Research, NHRI, Taiwan
1999 Board member, Sino-American Cancer Foundation, Taiwan
1997-2001 Adjunct Attending physician, Department of Oncology, NTUH, Taiwan
1997 Senior Attending physician, Division of Cancer Research, NHRI, Taiwan
1997-2001 General Secretary, Chinese Oncology Society, Taiwan
1997 Chief, Hematology / Oncology, Cheng-Hsien Medical Center, Taiwan
1994-2003/07 Associate Professor, Internal Medicine, NDMC, Taiwan
1994-1996 Board member, Chinese BMT Society, Taiwan
1993 Chief, Medical Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan
1991-1992 Attending physician, Medical Mission in Republic of Central Africa
1989-1991 Visiting Scholar, Department of Pharmacology, Yale Medical School
1987-1989 Fellow of Medical Oncology Training Program, Institute of Biomedical Science, Academia Sinica, Taiwan
1987- Attending Physician, Hematology / Oncology, Tri-Service General Hospital, NDMC, Taiwan
1986 – 1987 Chief Resident, Division of Hematology / Oncology, Department of Internal Medicine, TSGH, NDMC, Taiwan
1982 – 1986 Resident, Department of Medicine, TSGH, NDMC, Taiwan
1981 – 1982 Internship training, Tri-Service General Hospital

HONORS & AWARDS

2013 第九屆奈米科技菁英獎
2011 Outstanding Poster Award, The 16th Annual Taiwan Joint Cancer Conference
2010 經濟部國家發明創新獎
2010 Outstanding Poster Award, The 15th Annual Taiwan Joint Cancer Conference
2008 Outstanding Poster Award, The 13rd Annual Taiwan Joint Cancer Conference
2007 Outstanding Poster Award, The 12nd Annual Taiwan Joint Cancer Conference
2006 Outstanding Poster Award, The 11th Annual Taiwan Joint Cancer Conference
2005 Outstanding Poster Award, The 10th Annual Taiwan Joint Cancer Conference
2005 徐千田防癌研究基金癌症傑出研究獎 (基礎組)
2004 Outstanding Poster award, The 9th Annual Taiwan Joint Cancer Conference
2003 Outstanding Poster award, The 8th Annual Taiwan Joint Cancer Conference
2001 Outstanding Poster award, The 6th Annual Taiwan Joint Cancer Conference

RESEARCH INTERESTS

Dr. Chang’s research interests focus on two areas: (1) identify the risk factors of chemotherapy-induced peripheral neuropathy; (2) discover neuroprotective compounds to against chemotherapy-induced peripheral neuropathy.

EXPERTISE

Medical Oncology, Cancer pharmacology and drug discovery

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

We have preclinical identified candidate lead compounds to protect paclitaxel- and oxaliplatin-induced peripheral neuropathy. Preclinical pharmacological studies are ongoing. In addition, we focus on studying the neuroprotective role of protease inhibitor in different animal models.

PUBLICATIONS
(A) Research Articles (From 2011)

  1. Cheung CHA, Cheng LT, Chang KY, Chen HH and Chang JY*. Investigations of the inhibitor-of-apoptosis protein (IAP), Survivin: the past, present and future. Frontiers in Bioscience, 16:952-961, 2011
  2. Hsieh, C.-L., Tseng, M.-H., Pan, R.-N., Chang, J.-Y., Kuo, C.-C., Lee, T.-H., Kuo, Y.-H.* Labdanecaryophyllic acid, a novel cytotoxic C35 terpenoid from Calocedrus macrolepis var. formosana. Tetrahedron Letters 52(4):515-517, 2011
  3. Chuang, H.-Y., Chang, JY (co-first author), Lai, M.-J., Kuo, C.-C., Lee, H.-Y., Hsieh, H.-P., Chen, Y.-J., Chen, L.-T., Pan, W.-Y., Liou, J.-P. 2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. ChemMedChem 6: 450-456, 2011
  4. Hsieh CC, Lee HY, Nein CY, Kuo CC, Chang CY, Chang JY* and Liu JP*. Synthesis and biological evaluation of 4-aroyl-6,7,8-trimethoxyquinones as a novel class of anticancer agent. Molecules 16 (3): 2274-2284, 2011
  5. Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Hwang LL, Ho PY, Chen TY, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Huang DR, Chern JH, Chang JY, Chao YS and Chen CT. BPR0C261 is a novel orally active antitumor agent with antimitotic and antiangiogenic activities. Cancer Science 102 (1): 182-191, 2011
  6. Cheung CHA, Coumar MS, Chang JY* and Hsieh HP*. Aurora kinase inhibitors patents and agents in clinical testing: an update (2009-2010). Experts Opinion on Therapeutic Patents 21 (6): 857-884, 2011 (invited review)
  7. Lee HY, Chang JY (Co-first author), Chang LY, Lai WY, Lai MJ, Shih KH, Kuo CC, Chang CY and Liu JY. Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Organic and Biomolecular Chemistry 9(9):3154-3157, 2011
  8. Tung YS, Morhan C, Wu YS, Shiao HY, Chang JY, Liu JP, Paritosh S, Chang JW, Chang CY, Kuo CC, Yeh TK, Lin CY, Wu JS, Wu SY, Liao CC and Hiseh HP. Scaffold -hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic- heteroaromatics to identify orally-bioavailable anticancer agents. J Med Chem. 54(8):3076-80, 2011
  9. Ch’ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsiu CH, Tien YW, Chen JS, Hiseh RK, Lin BW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL and Chen LT. Induction chemotherapy with gemcitabine, oxaliplatin, 5-FU/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan Cooperative Oncology group phase II study. Int. J of Radiation Oncology, Biology, Physics. 81(5): e749-757, 2011
  10. Charoenfuprasert S, Yang YY, Lu YC, Chao KC, Chu PY, Lai CR, Hsu KF, Chang KC, Chen YC, Chen LT, Chang JY, Leu SJ and Shih NY. Identification of salt-inducible kinase 3 as novel tumor antigen associated with tumorigenesis of ovarian cancer. Oncogene 18: 30 (33): 3570-3584, 2011
  11. Lai, M.-J., Chang, J.-Y. (Co-first author), Lee, H.-Y., Kuo, C.-C., Lin, M.-H., Hsieh, H.-P., Chang, C.-Y., Wu, J.-S., Wu, S.-Y., Shey, K.-S., Liou, J.-P.* Synthesis and biological evaluation of 1-(4’-indolyl and 6’-quinolinyl)indoles as a new class of potent anticancer agents. European Journal of Medicinal Chemistry 46(9): 3625-9, 2011
  12. Chen, H.-H., Chiang, W., Chang, J.-Y., Chien, Y.-L., Lee, C.-K., Liu, K.-J., Cheng, Y.-T., Chen, T.-F., Kuo, Y.-H., Kuo, C.-C.* Antimutagenic Constituents of Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) with Potential Cancer Chemopreventive Activity. Journal of Agricultural and Food Chemistry Jun 22;59(12):6444-52 2011
  13. Yang, Y.-N., Chou, K.-M., Pan, W.-Y., Chen, Y.-W., Tsou, T.-C., Yeh, S.-C., Cheung, C.-H.A., Chen, L.-T., Chang, J.-Y*. Enhancement of Non-homologous End Joining DNA Repair Capacity Confers Cancer Cells Resistance to the Novel Selenophene Compound, D-501036. Cancer Letters, 309 (1): 110-118, 2011
  14. Cheung, C-H.A., Lin WS, Hsu TAJ, Hour TC, Ko SK, Lien TW, Courma MS, Liu JF, Lai WY, Lee TZ, Hsieh HP and Chang JY* BPR1K653, a novel aurora kinase inhibitor, displays potent anti-proliferative activity in MDR1 (pgp170)-mediated multi-drug resistant cancer cells. PLoS One, 6(8): e23485, 2011
  15. Kuo, C.-C*., Liu, T.-W., Chen, L.-T., Shiah, H.-S., Wu, C.-M., Cheng, Y.-T., Pan, W.-Y., Liu, J.-F., Chen, K.-L., Yang, Y.-N., Chen, S.-N., Chang, J.-Y.* Combination of Arsenic Trioxide and BCNU Synergistically Triggers Redox–mediated Autophagic Cell Death in Human Solid Tumors. Free Radical Biology and Medicine, 51: 2195-2209, 2011
  16. Chang, K.-Y., Tsai, S.-Y., Wu, C.-M., Yen, C.-Y., Chuang, B.-F., and Chang, J.-Y*. Novel PI3K/mTOR inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clinical Cancer Research, 17(22):7116-7126, 2011
  17. Lee, H.-Y#, Chang, J.-Y#., Nien, C.-Y., Kuo, C.-C., Lai, W.-Y., Chang, C.-Y., and Liou, J.-P. 5-amino-2-aroylquinolones as highly potent tubulin polymerization inhibitors. Part 2 the impact of bridging groups at C2 position. J Med Chem. 22: 54(24): 8517-25,2011 (# equally contributed)
  18. Hsieh CL, Tseng MH, Pan RN, Chang JY, Kuo CC, Lee TH and Kuo YH. Novel terpenoids from Calocedrus macrolepis var. formosana. Chem Biodivers. 8(10): 1901-7, 2011
  19. Chou, L.-H., Lin, P.-C, Chang J.-S,, Chu, P.-Y., Lee, P.-K., Chen, S.-N., Cheng, Y.-M., Lee, J.-C., Chang, J.-Y., and Liu, T.-W*. Differences in frequencies of K-ras c12-13 genotypes by gender and pathological phenotypes in colorectal tumor measured using the allele discrimination method. Environmental and Molecular Mutagenesis. 53(1): 22-31, 2012
  20. Shih, Y.-T, Wang, M.-C, Peng, H,-H, Chen, T,-F, Chang, J.-Y and Chiu JJ. Modulation of chemotactic and pro-inflammatory activities of endothelial progenitor cells by hepatocellular carcinoma. Cell Signal 24: 779-793, 2012
  21. Chen, K.-L., Chang, W.-S. W., Lin, C.-C., Cheung, C.-H.A., Kuo, C.-P., Kuo, C.-C., Chang, Y.-H., Liu, K.-J., Chang, J.-Y.* Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Letters  317:89-98, 2012
  22. Lee K.D., Pai, M.Y., Hseu, C.C., Chen, C.C., Chen, Y.L., Chu, P.Y., Lee, C.H., Chen, L.T., Chang, J.Y., Hung, T.H., Hsiao, S.H., and Leu, L.W. Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells. Biochem Biophys Res Commun. 15: 422(4): 578-585, 2012
  23. Lee H.Y., Lee, L.W., Nien, C.Y., Kuo, C.C., Lin, P.Y., Chang, C.Y., Chang J.Y.* and Liou, J.P.* Application of Suzuki Acylation, Sonogashira Ethynylation, and Rosenmund-von Braun cyanation in the exploration of substation effect on anticancer activity of 2-aroylquinolines. Organic and Biomolecular Chemistry 10(48):9593-600, 2012
  24. Huang CC, Tsai ST, Kuo CC, Chang JS, Jin YT, Chang JY* , HsiaoJR*. Arginine deprivation as a new treatment strategy for head and neck cancer. Oral Oncology, 48(12): 1227-35, 2012.
  25. Shiah H.S., Chen, C.Y., Dai, C.Y., Hsia, C.F., Lin, Y.Z., Su, W.C., Chang, J.Y. Whang-Peng, J., Lin, P.W., Huang, J.D., and Chen, L.T. Randomized clinical trial: comparison of two evirolimus dosing schedules in patients with advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 37: 62-74, 2013
  26. Lee C.H., Wong T.S. Chan JYW, Cheng A.J., Chen Y.J., Lu S.C., Chang J. SM., Li C.I., Hsiao S.H., Leu Y.W., Hsiao J.R*., and Chang J.Y*. Epigenetic regulation of the X-linked tumor suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. J Pathology 230: 298-309, 2013
  27. Hsiao J.R., Ou, C.Y., Lo, H.I., Huang, C.C., Lee, W.T., Huang, J.S., Chen, K.C., Wong, T.Y., Tsai, S.T., Yen, C.J., Wu, Y.H., Heush W.T., Yang, M.W., Wu, S.Y., Chang, J.Y., Chang, K.Y., Lin, C.L., Wang, F.T., Wang, Y.H., e Y.L., Yang, H.C., and Chang, JS. Allergies and risk of head and neck cancer: an original study plus meta-analysis. PLoS One. 8(2): e55138, 2013
  28. Lien, S.C., Wei, S.Y., Chang, S.F., Chang, M. DS., Chang, J.Y.* and Chiu, J.J*. Activation of PPAR-α induces cell cycle arrest and inhibits transforming growth factor-beta1 induction of smooth muscle cell phenotype in 10T1/2 mesenchymal cells. Cellular signalling 25(5):1252-1263, 2013
  29. Chiang, N.J., Lin, C.Y., Liu, J.P., Kuo, C.C., Chang, C.Y., Cheng, L.T., and Chang, J.Y*. A novel synthetic microtubule inhibitor, MPT214, exhibits antitumor activity in human cancer cells through mitochondria-dependent intrinsic pathway. PLoS One. 8(3):e58953, 2013
  30. Cheng Y.C., Liu, J.P., Kuo, C.C., Lai, W.Y., Shih, K.H., Chang, C.Y., Pan, W.Y., Tseng, J.T. and Chang, J.Y*. MPT098, a novel microtubule inhibitor, destabilizes hypoxia-inducible-1mRNA through decreasing nuclear-cytoplasmic translocation of RNA binding protein, HuR. Mol. Cancer Therapeutics, 12(7): 1-11, 2013
  31. Kuo YY, Lin HP, Huo C, Su LC, Yang J, Hsiao PH, Chiang HC, Chung CJ, Wang HD, Chang JY, Chen YW, Chuu CP. Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of Akt signaling. IJMS, 14(5): 8801–8817, 2013
  32. Chen, Y.T., Chen, Y.F., Chiu, W.T., Liu, K.Y., Liu, Y.L., Chang, J.Y., Chang, H.C., and Shen, M.R. Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cells behaviors. Cancer Research 73(14): 4500-9, 2013
  33. Chang K.Y., Tsai, S.Y., Chen, S.H., Tsou, H.H., Yen, C.J., Liu, K.J., Fang, S.L. Wu, H.C., Chung, B.F., Chou, S.W., Tang, CK, Liu, S.Y., Lu, P.J., Yen, C.Y* and Chang,J.Y*. Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. Journal of Biomedical Science , 20(1): 43, 2013
  34. Lin CY, Huo C, Kuo LK, Hiipakka RA, Jones RB, Lin HP, Hung Y, Su LC, Tseng JC, Kuo YY, Wang YL, Fukui Y, Kao YH, Kokontis JM, Yeh CC, Chen L, Yang SD, Fu HH, Chen YW, Tsai KK, Chang JY, Chuu CP. Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells. PLoS One 13;8(6): e65734, 2013
  35. Huang, C.C., Chen, K.L., Cheung ACH, and Chang, J.Y.* Autophage induced by cathepsin S inhibition induces ROS production, oxidative DNA damage and cell death via xanthine oxidase. Free Radical Biology and Medicine  65: 1473-1486, 2013
  36. Chen CC, Chu CB, Liu KJ, Huang CY, Chang JY, Pan WY, Chen HH, Cheng YH, Lee KD, Chen MF, Kuo CC and Chen LT. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochemical Pharmacology, 86(7): 872-887, 2013
  37. Lee WH, Liu HE, Chang JY, Liou JP and Huang HM. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel resistant cell. Pharmacology, 16; 92(1-2): 90-98, 2013
  38. Cheung CHA, Huang CC, Lee JYC, Cheng SM, Chang YC, Huang YC, Cheng SH and Chang JY*. Survivin-biology and potential as a therapeutic target in oncology. OncoTargets and Therapy. 6:1-10, 2013 (invited review)
  39. Lien SC, Chang SF, Lee PL, Wei SY, Chang MD, Chang J.Y*, Chiu JJ*. Mechanical regulation of cancer cell apoptosis and autophage: role of bone morphogenetic protein, smad 1/5, and p38 MAPK. Biochem. Biophys Acta 1833(12): 3124-3133, 2013
  40. Lee HY, Pan SL, Su MC, Liu YM, Kuo CC, Chang YT, Wu JS, Nien CY, Mehadiratta, S, Chang CY, Wu SY, Lai MJ, Chang JY* , Liu JP*. Furanyl-azaindoles: potent anticancer agents in vitro and in vivo. J Med Chem 56: 8008-8018, 2013
  41. Weng TY, Huang SS, Yen MC, Lin CC, Chen YL, Lin CM, Chen WC, Wang CY, Chang JY, Lai MD. A novel cancer therapeutic employing thrombospondin-1 in dendritic cells. Mol Ther, 22(2): 292-302, 2013
  42. Chang JS, Lo HI, Wong TY, Huang CC, Lee WT, Tsai ST, Chen KC, Yen CJ, Wu YH, Hsueh WT, Yang MW, Wu SY, Chang KY, Chang JY, Ou CY, Wang YH, Weng YL, Yang HC, Wang FT, Lin CL, Huang JS, Hsiao JR. Investigating the association between oral hygiene and head and neck cancer. Oral Oncology. 49(10):1010-7, 2013
  43. Yen YC, Shiah SG, Chu HS, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AY, Lu YC and Cheng YW. Reciprocal regulation of microRNA- 99a and insulin-like growth factor 1 I receptor signaling in oral squamous carcinoma cells. Mol Cancer  10;13(1):6, 2014
  44. Sheu J. JC., Lee C.C., Hua C.H., Lai M.T., Lee S.C., Cheng J., Chan C., Chao S. CC., Li C.I., Chen J.Y., Chang J.Y and Lee C.H. LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPH1 signaling and extracellular matrix remodeling. Oncogene 33: 1375-1384, 2014
  45. Chang CY, Chuang HY, Lee HY, Yeh TK, Kuo CC, Chang JY* ,Liou JP*. Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxyphenones. Eur J Med Chem 77: 306-314, 2014
  46. Chen YP, Lin HJ, Chen JS, Tsai MY, Hsieh HP, Chang JY, Chen NF, Chang KC, Huang WT, Su WC, Yang ST, Chang WC, Hung LY, Chen TY. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to aurora kinase-A inhibitors. Int J Cancer, 135 (3): 751-62, 2014
  47. Fang WT, Fan CC, Li SM, Jang TH, Lin HP, Shih NY, Chen CH, Wang TY, Huang SF, Lee AY, Liu YL, Tsai FY, Huang CT, Yang SJ, Yen LJ, Chuu CP, Chen CY, Hsiung CA, Chang JY, Wang LH, Chang IS, Jiang SS. Downregulation of a tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma. Int J Cancer, 15: 135(4): 809-19, 2014
  48. Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone or combination with erlotinib. Cell Death Dis. 5: e1162, 2014
  49. Tsai ST, Wong TY, Ou CY, Fang SY, Chen KC, Hsiao JR, Huang CC, Lee WT, Lo HI, Huang JS, Wu JL, Yen CJ, Hsueh WT, Wu YH, Yang MW, Lin FC, Chang JY, Chang KY, Wu SY, Liao HC, Lin CL, Wang YH, Weng YL, Yang HC, Chang JS. The interplay between alcohol consumption, oral hygiene, ALDH2 and ADH1B in the risk of head and neck cancer. Int J Cancer, 15: 135(10): 2424-36, 2014
  50. Chiu WH, Chen HH, Chang JY, Luo SJ, Li CL, Chen CL, Su WC, Lin CF. Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells. Cancer Lett. 349(2): 144-51, 2014
  51. Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Lin YM, Liu JF, Yeh TC, Wang JC, Chang CY, Chang JY* and Liu JP*. Azaindolylsulfonamides, a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. J Med Chem, 57(10): 4009-22, 2014
  52. Wang PW, Abedini MR, Yang LX, Ding AA, Figeys D, Chang JY, Tsang BK, Shieh DB. Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer. Int J Cancer, 15; 135 (12): 2760-9, 2014
  53. Huang CC, Lee WT, Tsai ST, Ou CY, Lo HI, Wang TY, Fang SV, Chen KC, Huang JS, Wu JC, Yen CJ, Hsueh WE, Wu YH, yang MW, Lin FC, Chang JY, Chang KW, Wu SY, Hisao JR, Lin CL, Wang YH, Wang YL, yang HC and Chang JS*. Tea consumption and risk of head and neck cancer. PLoS One 9 (5): e96507, 2014
  54. Su WP, Wu CK, Chang SB, Lin YJ, Yang WB, Hung JJ, Chiu WT, tseng SF, Tseng YL, Chang JY, Su WC and Liao HJ. Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin- resistant phenotype in nasopharyngeal carcinoma. Oncotarget, 5(15): 6323-37, 2014
  55. Mehndiratta S, Chang YF, Lai MJ, Lee HY, Chen MC, Kuo CC, Chang CY, Chang JY*, Liou JP*. Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. Bioorganic and Medicinal Chemistry, 22(17): 4917-23, 2014
  56. Weng TY, Yen MC, Huang CT, Hung JJ, Chen YL, Chen WC, Wang CY, Chang JY, Lai MD. DNA vaccine elicits efficiency antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model. Gene Ther. 21 (10): 888-96, 2014
  57. Shiah SG, Hsiao JR, Chang WM, Chen YW, Jin YT, Wong TY, Huang JS, Tsai ST, Hsu YM, Chou ST, Yen YC, Jiang SS, Shieh YS, Chang IS, Hsiao M and Chang JY*. Downregulated miRNA-329 and miRNA-410 promote tumor proliferation and invasion through Wnt/b-catenin signaling pathway by targeting Wnt-7b in oral squamous cell carcinoma. Cancer Res. 74(24); 7560-72, 2014
  58. Cheng S, Chang Y, Liu C, Lee J, Chan H, Kuo C, Lin K, Tsai S, Chen S, Li C, Leung E, Kanwar J, Huang C, Chang JY, Cheung C. YM155 down-regulates surviving and XIAP, moderates autophagy, and induces autophagy -dependnet DNA repair in breast cancer cell. British J Pharmacology, 172(1): 214-34, 2015
  59. Lee WT, Huang CC, Chen KC, Wong TY, Ou CY, Tsai ST, Yen CJ, Fang SY, Lo HI, Wu YH, Hsueh WT, Yang MW, Lin FC, Hsiao JR, Huang JS, Chang JY, Chang KY, Wu SY, Lin CL, Wang YH, Weng YL, Yang HC, Chang JS. Genetic polymorphisms in the prostaglandin pathway genes and risk of head and neck cancer. Oral Dis 2(12): 207-15, 2015.
  60. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY*, Chen LT*. Phase I study of nanoliposomal irinitecan (PEP02) in advanced solid tumor patients. Cancer Chemotherapy and Pharmacology, 75: 579-586, 2015
  61. Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT; on behalf of the Taiwan Cooperative Oncology Group. A Kras-mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 26(5): 943-9, 2015
  62. Chen SH, Kuo, CC, Li CF, Cheung CH, Tsou TC, Chiang HC, Yang YN, Chang SL, Lin LC, Pan HY, Chang KY and Chang JY*.O6-Methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. Int J Cancer, 137(6): 1291-305, 2015
  63. Chen SJ, Kuo CC, Pan HY, Tsou TS, Yeh SC and Chang JY*. Mechanistic basis of a combination of D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant cervical cancer cell in vitro and in vivo. Biochemical Pharmacology, 95: 28-37, 2015
  64. Huang CC, Lee CC, Lin HH, Chen MC, Lin CC and Chang JY*. Autophage-regulated ROS from xanthine oxidase triggers acts as early effector for triggering late mitochondria-dependent apoptosis in cathepsin S-targeted tumor cells. PLoS One 10(6): e0128045, 2015
  65. Lee HY, Lai MJ, Chuang HY, Kuo CC, Chang CY, Chang JY*, Liou JP*. Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5,-trimethoxybenzenes. Bioorganic and Medicinal Chemistry. 23:4230-4236, 2015
  66. Chen KC, Hsueh WT, Ou CY, Huang CC, Lee WT, Fang SY, Tsai ST, Huang JS, Wong TY, Wu JL, Yen CJ, Wu YH, Lin FC, Yang MW, Chang JY, Liao HC, Wu SY, Hsiao JR, Lin CL, Wang YH, Weng YL, Yang HC, Chen YS, Chang JS. Alcohol drinking obliterates the inverse association between serum retinol and risk of head and neck cancer. Medicine (Baltimore) 94(26) :e1064, 2015
  67. Chen HH, Wang TC, Lee YC, Shen PT, Chang JY, Yeh TK, Huang CH, Chang HH, Cheng SY, Lin CY, Shih C, Chen CT, Liu WM, Chen CH, Kuo CC. A novel Nrf2/ARE activator, trans-Coniferyaldehyde, induces HO-1-mediated defense mechanism through a novel signaling pathway: dual p38a/MAPKAPK-2 and PK-N3 implication. Chem Res Toxicol. 28(9): 1681-92, 2015.
  68. Chen LH, Sun YT, Chen YF, Lee MY, Chang LY, Chang JY, Shen MR. Integrating image-based high-content screening with mouse models identifies 5-hydroxydecanoate as neuroprotective drug foe paclitaxel-induced neuropathy. Mol Cancer Ther 14(10): 2206-14, 2015
  69. Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC, Chiu CC, Chen LT, Chang JY, Hsiao SH, Leu YW. Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cell. Cancer Cell Int. 2015 (accepted)
  70. Chang KM, Chen HH, Wang TC, Chen IL, Chen YT, Yang SC, Chen YL, Chang HH, Huang CH, Chang JY, Shih C, Kuo CC, Tzeng CC. Novel oxime- bearing coumarin derivatives act as potent Nrf2/ARE activators in vitro and in mouse model. Eur J Med Chem. 106(1): 60-74, 2015
  71. Yen YC, Hsiao JR, Jiang SS, Chang JS, Wang SH, Shen YY, Chen CH, Chang IS, Chang JY, Chen YW. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous carcinoma cell by requirement of integrin b1. Oncotarget, Dec.8: 6(34): 1837-53, 2015
  72. Nepali K, Kumar S, Huang HL, Kuo FC, Lee CH, Kuo CC, Yeh TK, Li YH, Chang JY, Liou JP, Lee HY. 2-aroylquinolone-5,8-diones as potent anticancer agents display tubulin and heat shock protein 90 inhibition. Org Biomol Chem.  Dec 23;14(2):716-23, 2015
  73. Shiah,SG, Shieh YS and Chang JY*. The role of Wnt signalling in squamous cell carcinoma. J Dent Res, 95(2): 129-134, 2016 (IF: 4.139; Rank: 1/87 invited review)
  74. Su JL, Su CM, Wang MY, Hong CC, Chen HA, Su YH, Wu CH, Huang MT, Chang YW, Jiang SS, Sung SY, Chang JY, Chen LT, and Chen PS. miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene, May 3; 35(9): 1134-42, 2016
  75. Cheng CW#, Hsiao JR#, Fan CC#, Lo YK, Tzen CY, Wu LW, Fang WY, Cheng AJ, Chen CH, Chang IS, Jiang SS, Chang JY, and Alan Yueh-Luen Lee*.Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma. Molecular Carcinogenesis, May; 55(5): 499-513, 2016
  76. Peng HY, Jiang SS, Hsiao JR, Hsiao M, Hsu YM, Wu, GH, Chang WM, Chang JY, Jin SL and Shiah SG.IL-8 induces miR-424-5p expression and modulates SOCS2/STAT3 signaling pathway in oral squamous cell carcinoma. Molecular Oncology, June 10 (6): 895-909, 2016
  77. Chiang NJ, Chang JY, Shan YS, Chen LT. Development of nanoliposomal irinotecan (nal-IR1, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert Opin Pharmacother. Jul; 17(10): 1413-20, 2016
  78. Cheng CM, Shiah SW, Huang CC, Hsiao JR and Chang JY*. Upregulation of miR-455-5P by the TGF-β–SMAD signaling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. J Pathology, sep 240(1): 38-49, 2016
  79. Huang CC, Lee CC, Lin HH and Chang JY*. Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors. Scientific Reports, July 8; 6: 29256, 2016
  80. Chen SJ, Kuo CC, Pan HY, Tsou TC, Yeh SC and Chang JY*. Desferal regulates hCTR1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Oncotarget, 7 (31): 49310-49321,2016
  81. Peng HY, Cheng YC, Hsu YM, Wu GH, Kuo CC, LIou JP, Chang JY, Jin SL and Shiah SG. MPT0B098, a microtubule inhibitor, suppresses JAK2/STAT3 signaling pathway through modulation of SOCS3 expression in oral squamous cell carcinoma. PLoS one, July 1; 11(7): e0158440, 2016
  82. Liu KJ, Chao TY, Chang JY, Cheng AL, Ch’ang HJ, Kao WY, Wu YC, Yu WL, Chung TR, Whang-Peng J.A phase 1 clinical study of immunotherapy for advanced colorectal cancer using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequently IL-2 treatment. J Biomed Sci. 2016 Aug 24;23 (1):64.
  83. Wu YH, Yen CJ, Hsiao JR, Ou CY, Huang JS, Wong TY, Tsai ST, Huang CC, Lee WT, Chen KC, Fang SY, Wu JL, Hsueh WT, Lin FC, Yang MW, Chang JY, Liao HC, Wu SY, Lin CL, Wang YH, Weng YL, Yang HC, Chen YS, Chang JS. A comprehensive analysis of the association between tobacco free betel quid and head and neck cancer in Taiwanese men. PLoS One. 2016 Oct 25;11(10):e0164937
  84. Liao HC, Wu SY, Ou CY, Hsiao JR, Huang JS, Tsai ST, Huang CC, Wong TY, Lee WT, Chen KC, Fang SY, Wu JL, Huang TT, Wu YH, Hsueh WT, Yen CJ, Yang MW, Lin FC, Lai YH, Chang JY, Lin CL, Wang YH, Weng YL, Yang HC, Chen YS, Chang JS. Allergy symptoms, total serum immunoglobulin E and risk of head and neck cancer. Cancer Causes Control, 27(9): 1105-15, 2016 Sep
  85. Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Lai TC, Wu GH, Hsu YM, Chi LH, Hsiao JR, Chen CL, Chang JY, Shieh YS, Hsiao M, Shiah SG. Dysregulation of Runx2/Activin A upon miR376C downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma. Cancer Res. 76(14): 7140-7150, 2016 Dec. 15
  86. Wang SH, Chang JS, Hsiao JR, Yen YC, Jiang SS, Liu SH, Chen YL, Shen YY, Chang JY, Chen YW. Tumor cell-derived WNT5B modulates in vitro lymphangiogenesis via induction of partial epithelial-mesenchymal transition of lymphatic endothelial cells. Oncogene. 2017Mar: 36(11): 1503-1515
  87. Tien YE, Li CJ, Liou JP, Chang JY, Huang JD. Pharmacokinetics and protein binding of MPT0B292. Biopharm Drug Dispos. 2017 Feb 1.
  88. Chen YF, Chen LH, Yeh YM, Wu PY, Chen YF, Chang LY, Chang JY, Shen MR. Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy. Sci Rep. 2017 Mar 28;7:45366
  89. Hsu JY, Chang JY, Chang KY, Chang WC, Chen BK. Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamaous cell carcinoma metastasis via up-regulation of fibronectin. FASAB J 2017 Oct;31(10):4265-4276
  90. Su WP, Ho YC, Wu CK, Hsu SH, Shiu JL, Huang JC, Chang SB, Chiu WT, Hung JJ, Liu TL, Wu WS, Wu PY, Su WC, Chang JY, Liaw H. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Sci Rep. 2017 Jun 20;7(1):3879.
  91. Hou PC, Li YH, Lin SC, Lin SC, Lee JC, Lin BW, Liou JP, Chang JY, Kuo CC, Liu YM, Sun HS, Tsai SJ. Hypoxia-induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. Cancer Res. 2017 Jun 26.
  92. Yeh YM, Hsu SJ, Lin PC, Hsu KF, Wu PY, Su WC, Chang JY, Shen MR. The c.1085A>C genetic variant of CSF1R gene regulates tumor immunity by altering proliferation, polarization and function of macrophages. Clin Cancer Res. 2017 Jul 19
  93. Huang CC, Hsiao JR, Lee WT, Lee YC, Ou CY, Chang CC, Lu YC, Huang JS, Wong TY, Chen KC, Tsai ST, Fang SY, Wu JL, Wu YH, Hsueh WT, Yen CJ, Wu SY, Chang JY, Lin CL, Wang YH, Weng YL, Yang HC, Chen YS, Chang JS. Investigating the association between alcohol and risk of head and neck cancer in Taiwan. Sci Rep. 2017 Aug 29;7(1):9701.
  94. Chang CC, Lee WT, Lee YC, Huang CC, Ou CY, Lin YH, Huang JS, Wong TY, Chen KC, Hsiao JR, Lu YC, Tsai ST, Lai YH, Wu YH, Hsueh WT, Yen CJ, Wu SY, Chang JY, Fang SY, Wu JL, Lin CL, Weng YL, Yang HC, Chen YS, Chang JS. Investigating the association between diet and risk of head and neck cancer in Taiwan. Oncotarget Oct 24;8(58):98865-98875, 2017
  95. Chen HH, Chang HH, Chang JY, Tang YC, Cheng YC, Lin LM, Cheng SY, Huang CH, Sun MW, Chen CT, Kuo CC Enhanced B-Raf-mediated Nrf2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells. Free Radic Biol Med. 2017 Oct 25
  96. Weng TY, Li CJ, Li CY, Hung YH, Yen MC, Chang YW, Chen YH, Chen YL, Hsu HP, Chang JY, Lai MD. Skin delivery of Clec4a small hairpin RNA elicited an effective antitumor response by enhancing CD8± immunity in vivo. Mol Ther Nucleic Acids. Dec 15;9:419-427, 2017
  97. Tsai IT, Kuo CC, Liou JP, Chang JY*. Novel microtubule inhibitorMPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Biomed Sci. 2018 Mar 28;25(1):28
  98. Hsiao JR, Chang CC, Lee WT, Huang CC, Ou CY, Tsai ST, Chen KC, Huang JS, Wong TY, Lai YH, Wu YH, Hsueh WT, Wu SY, Yen CJ, Chang JY, Lin CL, Weng YL, Yang HC, Chen YS, Chang JS. The interplay between oral microbiome, life style factors and genetic polymorphism in the risk of oral squamous carcinoma. Carcinogenesis. 2018 Apr 13.
  99. Weng TY, Wu HF, Li CY, Hung YH, Chang YW, Chen YL, Hsu HP, Chen YH, Wang CY, Chang JY, Lai MD. Homoharrigitonine induced immune alteration  for an efficient anti-tumor response in mouse models of non-small cell lung adenocarcinoma expressing K-ras mutation. Sci Rep. 2018 May 29;8(1):8216
  100. Hsu SH, Chen SH, Kuo CC and Chang JY*.Ubiquitin- conjugating enzyme E2B regulates ubiquitination of O6-methylguanine methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cell. Biochemical Pharmacology 158: 327-338, Dec. 2018
  101. Lee CC, Cheng YC, Chang CY, Lin CM and Chang JY*. Alpha-tubulin acetyltransferase/MEC17 regulates cancer cell migration and invasion through epithelial-mesenchymal transition suppression and cell polarity disruption. Sci  Rep. Non. 30:8(1): 17477, 2018
  102. Lai MC, Ojha R, Lin MH, Liu YM, Lee HY, Lin TE, Hsu KC, Chang CY, Chen MC, Nepali K, Chang JY*, Liu JP*. 1-aroylsulfonyl indoline-bezamides as a new antitubulin agents, with inhibition of histone deacetylase. Eur J Med Chem. Jan 15;162:612-630, 2019
  103. Lee WT, Hsiao JR, Ou CY, Huang CC, Chang CC, Tsai ST, Chen KC, Huang JS, Wong TY, Lai YH, Wu YH, Hsueh WT, Wu SY, Yen CJ, Chang JY, Lin CL, Weng YL, Yang HC, Chen YS, Chang JS. The influence of pre-diagnosis of alcohol consumption and the polymorphisms of ethanol metabolizing genes on the survival of head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):248-257.
  104. Lin PC, Yeh YM, Wu PY, Hsu KF, Chang JY, Shen MR. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer. Sci Rep, Mar 8;9(1):3931, 2019
  105. Hsing EW, Shiah SG, Peng HY, Chen YW, Chuu CP, Hsiao JR, Lyu PC, Chang JY*. TNF-α-induced m450A mediates TMEM 182 expression to promote oral squamous cell carcinoma motility. PLoS One. Mar 20;14(3):e0213463, 2019
  106. Chang CC, Lee WT, Hsiao JR, Ou CY, Huang CC, Tsai ST, Chen KC, Huang JS, Wong TY, Lai YH, Wu YH, Hsueh WT, Wu SY, Yen CJ, Chang JY, Lin CL, Weng YL, Yang HC, Chen YS, Chang JS. Cancer Med. April; 8(4): 1854-1864, 2019
  107. Wang SH, Liou GG, Liu SH, Chang JS, Hsiao JR, Yen YC, Chen YL, Wu WL, Chang JY, Chen YW. Laminin γ2-enriched extracellular vesicles of oral squamous cell carcinoma enhance in vitro lymphangiogenesis via integrin  α3-dependent uptake by lymphatic endothelial cell. Int J Cancer, June 1; 144(11): 2795-2810, 2019
  108. Yen CJ, Tsou HH, Hsieh CY, Chen CY, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY and Chang KY. Sequential neoadjuvant biochemotherapy with cetuximab, paclitaxel and cisplatin followed by cetuximab-based bioradiotherapy in high risk locally advanced oral squamous cell carcinoma: final analysis of phase 2 clinical trial. Head Neck, June; 41(6): 1703-1712, 2019
  109. Hsiao JR, Lee WT, Ou CY, Huang CC, Chang CC, Tsai ST, Chen KC, Huang JS, Wong TY, Lai YH, Wu YH, Hsueh WT, Wu SY, Yen CJ, Chang JY, Lin CL, Weng YL, Yang HC, Chen YS, Chang JS. Validation of alcohol flushing questionnaire to identify the ALDH2 status in a case-control study of head and neck cancer. Alcohol Clin Exp Res. June 43(6): 1225-1233, 2019
  110. Lin HH, Chen SJ, Shen MR, Huang YT, Hsieh HP, Lin SY, Lin CC, Chang WW, Chang JY*. Lysosomal cysteine protease cathepsin S is involved in cancer cell motility by regulating store-operated Ca +2 entry. Biochim Biophys Acta Mol Cell Res. 1866, 118517 Jul 21,2019
  111. Chen SH, Chang JY*. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int. J. Mol. Sci. 20(17), 4136, 2019,
  112. Lai CH, Chang JY, Wang KC, Lee FT, Wu HL and Cheng TL. Pharmacological inhibition of cathepsin S suppresses aortic aneurysm in mice. Eur. J. Vas. Endovas. Surg. 2020
  113. Huang HW, Wu PY, Su PF, Li CI, Yeh YM, Lin PC, Hsu KF, Shen MR, Chang JY* and Lin CCK*. A simplified diagnostic classification scheme of chemotherapy-induced peripheral neuropathy. Disease Markers, Jan. 25; 2020:3402108, 2020
  114. Shiah SG, Hsiao JR, Chang HJ, Hsu YM, Wu GH, Peng HY, Chou ST, Kuo CC and Chang JY*. MiR-30a and miR-379 modulate retinoic acid pathway by targeting DNA methyltransferase 3B in oral cancer. J Biomedical Science. 2020 Apr 2; 27(1):46.
  115. Chen YL, Tsai WH, Ko YC, Lai TY, Cheng AJ, Shiah SG, Hsiao JR, Chang JY and Lin SF. Discoidin domain receptor-1 (DDR1) is involved in angiolymphatic invasion in oral cancer. Cancers, 2020 Mar 31;12(4).
  116. Fang YW, Kuo YZ, Chang JY, Hsiai JR, Kao HM, Tsai ST and Wu LH. The tumor suppressor TGFRBR3 blocks lymph node metastasis in head and neck cancer. Cancers, 27; 12(6): 1375, 2020Fang YW, Kuo YZ, Chang JY, Hsiai JR, Kao HM, Tsai ST and Wu LH. The tumor suppressor TGFRBR3 blocks lymph node metastasis in head and neck cancer. Cancers, 27; 12(6): 1375, 2020
  117. Hsiao, JR, Huang, CC, Ou, CY, Chang, CC, Lee, WT, Tsai, ST, Huang, JS, Chen, KC, Lai, YH, Wu, YH; Hsueh, WT, Wu, SY, Yen, CJ, Chang, JY, Lin, CL, Weng, YL, Yang, HC, Chen, YS, and Chang, Jeffrey. Investigating the health disparities in the association between lifestyle behaviors and the risk of head and neck cancer. Cancer Science, 111:2974-2986, 2020
  118. Ko, YC, Lai, TY, Hsu, SC, Wang, FH, Su, SY, Chen, YL,Tsai, ML,Wu, CC, Hsiao, JR, Chang, JY,Wu, YM, Robinson, DR,Lin, CY, Lin, SF. Index of cancer-associated fibroblasts is superior to the epithelial–mesenchymal transition score in prognosis prediction. Cancers, June 28; 12(7): 1718, 2020
  119. Chang YC, Kondapuram SK, Yang TH, Syed SB, Cheng SM, Lin TY, Lin YC, Coumar MS, Chang JY, Leung E, Cheung CHA. The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. Toxicology and Applied Pharmacology 401, Aug 15; 401: 115080, 2020
  120. Chen YL, Yen YC, Jang CW, Wang SH, Huang HT, Chen CH, Hsiao JR, Chang JY and Chen YW. Ephrin A4‑ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells. Sci Rep 11:664, 2021
  121. Chen SJ, Chen LH, Yeh YM, Lin CCK, Lin PC, Huang HW, Shen MR, Lin BW, Lee JC, Lee YF, Chiang HC and Chang JY*. Targeting lysosomal cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy. Theranostics, 11(10): 4672-4687, 2021
  122. Tsai HJ, Hsiah HS, Chang JY, Su WC, Chiang NJ and Chen LT. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Sci Rep Mar 1; 11(1): 4834, 2021
  123. Shiah, HS, Chiang NJ, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT. Phase I dose escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. The Oncologist, 26: e567-e579, 2021
  124. Chen SH, Hsiao SY, Chang KY and Chang JY*. New Insights into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis. Int. J. Mol. Sci. 22:2252, 2021
  125. Tang CH, Hsiao JR, Jiang SS, Chang JY, Chen PY, Liu KJ, Fang HL, Lin LM, Chen HH, Huang YW, Chen YT, Tsai FY, Lin SF, Chuang YJ and Kuo CC. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation. Theranostics, Mar 11; 11(11): 5232-5247, 2021
  126. Huang CC, Su, YC, Chang CC, Lee WT, Qu CY, Wu, YH, WU SY, Lan YH, Huang TS, Chen KC, Hsueh WT, Tsan ST, Yen CJ, Chang JY, Tsan ML, Lin CL, Weng YC, Yang HC, Chen YS, Hsiao JR and Chang JS. Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer. Cancer Medicine 10: 4075-4086,2021
  127. Hsu, HY; Yang, CW; Lee, YZ; Lin, YL; Chang, SY; Yang, RB; Liang, JJ; Chao, TL; Liao, CC; Kao, HC; Wu, SH; Chang, JY; Sytwu, HK; Chen, CT; Lee, SJ.  Remdesivir and cyclosporine synergistically inhibit the human coronaviruses OC43 and SARS-CoV-2. Frontiers in Pharmacology. 2021 Aug 13; 12: Article number 706901.
  128. Shiah SG*, Chou, ST, Chang JY * MicroRNAs: Their Role in Metabolism, Tumor Microenvironment, and Therapeutic Implications in Head and Neck Squamous Cell Carcinoma. Cancers, 13, 5604, 2021 (invited review).
  129. Liu YH, Chen YL, Lai TY, Ko YC, Chou YF, Chen PR, Hsiao JR, Chang JY, Shiah SG, Lee JW, Yang JL, Lin SF. Identification of Prognostic Biomarkers Originating from the Tumor Stroma of Betel Quid-Associated Oral Cancer Tissues. Front. Oncol. 16;11:769665, 2021
  130. Tang YC, Chang HH, Chen HH, Yao JY, Chen YT, Chuang YJ, Chang JY, Kuo CC. A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells. Journal of Food and Drug Analysis 29:638-652, 2021

(B) Books
1.吳秋文等主編: 胃癌的診斷與治療：胃癌之輔助化學治療。Pp 419-426

PATENTS FILED AND GRANTED

  1. Lee, K.H.; Zhou, X.M.; Wang, Z.Q.; Chang, J.Y.; Chen, H.X.; Cheng, Y.C.; Shen, Y.C.; Han, F.S.; Hu, H., Zhang, Y.L. Etoposide analogs. US 5332811, Jul. 26, 1994 ~ Jul. 26, 2011.
  2. Cheng, C.T.; Chang, J.Y. TW0228417B, Sep. 27, 2002 ~ Sep. 26, 2022.
  3. Su T.L.; Chou, T.C.; Chang, J.Y. 5-(9-Acridinylamino)-Toluidine Compounds. US6821983B2, Jul. 30, 2003 ~ Jul. 29, 2023.
  4. Su, T.L., Chou, T.C.; Chang, J.Y. 5-(9-Acridinylamino)-Toluidine Compounds. ROC 1-246508, Jan. 1, 2006 ~ Dec. 13, 2023.
  5. Hsieh, H.P.; Liou, J.P.; Chang, J.Y.; Chang, C.W. “Indole Compounds as Inhibitors of Tubulin Polymerisation for the Treatment of Angiogenesis-related Disorders,” EP1506960, 2010
  6. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, US7741495, June 22, 2010 – August 31, 2027.
  7. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, 日本特許第4521428號, May 28, 2010 – August 31, 2027.
  8. Hsieh, H.P.; Liou, J.P.; Chang, J.Y.; Chang, C. W. “Indole Compounds,” US7632955, December 15, 2009 – December 12, 2022.
  9. Hsieh, H.P.; Liou, J.P.; Chang, J.Y.; Chang, C. W. “芳香羰吲哚化合物,” TWI317634, December 1, 2009 – December 11, 2022.
  10. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, TWI315304, October 1, 2009 – August 31, 2027.
  11. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, KR10-0916989, September 4, 2009 – August 31, 2027.
  12. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, AU2007214336, June 4, 2009 – August 31, 2027.
  13. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, GB2441396, May 13, 2009 – August 31, 2027.
  14. Hsieh, H.P.; Liou, J.P.; Chang, J.Y.; Chang, C.W. “Indole Compounds,” US7528165, May 5, 2009 – December 12, 2022.
  15. Hsieh, H.P.; Tung, Y.S.; Liou, J.P.; Chang, J.Y.; Chao, Y.S. “Anti-Tumor Compounds,” US7456289, November 25, 2008 – December 15, 2025.
  16. Liou, J.P.; Chang, J.Y.; Hsieh, H.P. “Indoline-sulfonamides compounds”, NZ561060, November 13, 2008 – August 31, 2027.
  17. Hsieh, H.P.; Tung, Y.S.; Liou, J.P. Chang, J.Y.; Chao, Y.S. “Anti-Tumor Compounds,” TWI296195, May 1, 2008 – December 27, 2025.
  18. Hsieh, H.P.; Liou, J.P.; Chang, J.Y.; Chang, C.W. “Indole Compounds,” US6933316, August 23, 200

Comments are closed.